Virology


Select item(s)
Key Findings
No significant reduction in viral load was observed from baseline to day 15 among different treatment group patients (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine, and control group ).
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
HCQ did not significantly reduce the viral load in patients. No differences in the viral load reduction between the two groups of patients were observed (HCQ and control group).
PMID 33111169
Title No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Author(s) nameFaíco-Filho KS, Conte DD, de Souza Luna LK, Carvalho JMA, Perosa AHS, Bellei N.
Journal Braz J Microbiol
Impact factor1.67
Citation count2
Date of publishing2020 Dec
The combined treatment of Remdesivir and convalescent plasma therapy created an effective virological response for an immunocompromised patient who was previously struggling to control the viremia.
PMID 33103195
Title Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Author(s) nameMalsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, L√ľtgehetmann M, Rosien U, Jasper D, Peine S, Hiller J, Haag F, Schmiedel S, Huber S, Jordan S, Addo MM, Schulze Zur Wiesch J.
Journal Clin Infect Dis
Impact factor7.71
Citation count2
Date of publishing2020 Oct 26
Viral clearance within 14 days in the non-Arbidol group was lower than that of the Arbidol group.
PMID 33097047
Title Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Author(s) nameGao W, Chen S, Wang K, Chen R, Guo Q, Lu J, Wu X, He Y, Yan Q, Wang S, Wang F, Jin L, Hua J, Li Q.
Journal Virol J
Impact factor2.45
Citation count1
Date of publishing2020 Oct 23
No significant difference in the viral load reduction was observed between the treatment groups (HCQ and Control group).
PMID 33082342
Title A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Author(s) nameLyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, R√łsj√ł H, Dalgard O.
Journal Nat Commun
Impact factor11.8
Citation count4
Date of publishing2020 Oct 20
Viral loads decreased over time in 3 of 4 patients after Remdesivir treatment.
PMID 32418190
Title Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) nameDurante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R.
Journal Infection
Impact factor2.84
Citation count5
Date of publishing2020 Oct
Viral loads decreased over time in 3 of 5 patients after Remdesivir treatment. But two patients died due to disease severity.
PMID 32619764
Title Case report study of the first five COVID-19 patients treated with remdesivir in France
Author(s) nameDubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, Wicky PH, Le Pluart D, Kramer L, Rioux C, Le Hingrat Q, Houhou-Fidouh N, Yazdanpanah Y, Ghosn J, Lescure FX.
Journal Int J Infect Dis
Impact factor3.42
Citation count6
Date of publishing2020 Sep
This study reports that after 72 hours, 87.2% and 37.5% of patients showed negative SARS-CoV-2 conversion rates in the Convalescent plasma group and control group, respectively.
PMID 32492084
Title Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Author(s) nameLi L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z.
Journal JAMA
Impact factor14.78
Citation count197
Date of publishing2020 Aug 4
HCQ treated patients showed a significant reduction in viral load. The effect of HCQ increased when given in combination with Azithromycin.
PMID 32205204
Title Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Author(s) nameGautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D.
Journal Int J Antimicrob Agents
Impact factor4.6
Citation count1611
Date of publishing2020 Jul
This study compares the effect of convalescent plasma therapy against the control group on viral shedding and survival in COVID-19 patients with serious respiratory failure
PMID 32348485
Title Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Author(s) nameZeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS.
Journal J Infect Dis
Impact factor4.73
Citation count78
Date of publishing2020 Jun 16
4.4% of patients treated with hydroxychloroquine and azithromycin had a poor virological outcome (viral load was detectable after 10 days of treatment).
PMID 32387409
Title Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Author(s) nameMillion M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D.
Journal Travel Med Infect Dis
Impact factor3.42
Citation count132
Date of publishing2020 May-Jun
The mean baseline viral RNA loads were slightly higher in the Lopinavir-Ritonavir group than in the standard care group. But the percentage of patients with detectable viral RNA was similar in both groups.
PMID 32187464
Title A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
Author(s) nameCao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C.
Journal N Engl J Med
Impact factor37.91
Citation count1546
Date of publishing2020 May 7
The viral load significantly decreased over time in the combination group (beta-1b, Lopinavir-Ritonavir, and ribavirin) than in the control group (Lopinavir-Ritonavir).
PMID 32401715
Title Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Author(s) nameHung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY.
Journal Lancet
Impact factor43.38
Citation count352
Date of publishing2020 May 30
Viral load decreased over time comparably in both groups (Remdesivir group and placebo group).
PMID 32423584
Title Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Author(s) nameWang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C.
Journal Lancet
Impact factor43.38
Citation count738
Date of publishing2020 May 16
Critically ill, 5 COVID-19 patients were treated with the transfusion of "Convalescent- plasma" containing SARS-CoV-2 specific antibody. A significant reduction in viral load within 12 days of treatment was observed.
PMID 32219428
Title Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Author(s) nameShen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L.
Journal JAMA
Impact factor14.78
Citation count617
Date of publishing2020 Apr 28
COVID-19 patients were treated with Convalescent- plasma containing a high concentration of SARS-CoV-2 specific neutralizing antibodies (titers above 1:640). Serum SARS-CoV-2 RNA load disappeared within 3 to 6 days after CP therapy.
PMID 32253318
Title Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Author(s) nameDuan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X.
Journal Proc Natl Acad Sci U S A
Impact factor9.35
Citation count457
Date of publishing2020 Apr 28
Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells.
PMID 32198291
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R.
Journal Science
Impact factor20.57
Citation count479
Date of publishing2020 Apr 24
Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells.
PMID 32198291
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R.
Journal Science
Impact factor20.57
Citation count479
Date of publishing2020 Apr 24
A rapid fall of viral load reported over time, with 83% negative at Day 7 and 93% at Day 8 after receiving a combination of the drug (Hydroxychloroquine and Azithromycin).
PMID 32289548
Title Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Author(s) nameGautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D.
Journal Travel Med Infect Dis
Impact factor3.42
Citation count227
Date of publishing2020 Mar-Apr